ST 1898
Alternative Names: ACC-1898; ST-1898 - Beijing Scitech-Mq PharmaceuticalsLatest Information Update: 26 Jun 2026
At a glance
- Originator Beijing Scitech-Mq Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma; Renal cell carcinoma
- Phase II/III Thyroid cancer
Most Recent Events
- 25 Jun 2026 Phase-III clinical trials in Malignant melanoma (Metastatic disease, Monotherapy) in China (PO), prior to June 2026 (Beijing Scitech-Mq Pharmaceuticals pipeline, June 2026)
- 25 Jun 2026 Phase-III clinical trials in Renal cell carcinoma in China (PO), prior to June 2026 (Beijing Scitech-Mq Pharmaceuticals pipeline, June 2026).
- 28 Nov 2025 AccSalus Biosciences plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in January 2026 (PO), (NCT07252661)